BioNTech Q1 Earnings Call Highlights

Key Points

• BioNTech is shifting to a tumor‑centric, combination oncology strategy with pumitamab positioned as a potential immuno‑oncology backbone and management targeting more than 17 late‑stage/pivotal readouts through 2030, with key late‑stage data expected in 2026.
• Early lung cancer data for pumitamab showed a confirmed ORR of 46%, median PFS of 13.6 months and median OS of 27 months (71% ORR in PD‑L1 high squamous), while gotistobart and trastuzumab pamirtecan (T‑Pam) reported encouraging signals and regulatory designations, with pivotal/interim readouts anticipated in H2 2026.
• Financially, Q1 revenue declined to €118 million but the company holds €16.8 billion in cash, reaffirmed 2026 guidance (€2.0–2.3 billion revenue), and announced a $1 billion ADS buyback alongside a manufacturing consolidation that will affect ~1,800 roles and is expected to save about €500 million annually.

BioNTech NASDAQ: BNTX executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and manufacturing network consolidation.

Strategy: combination therapies and a tumor-focused approach

Chief Executive Officer and Co-founder Ugur Sahin said BioNTech’s long-term vision remains “translating science into survival,” arguing that cancer’s complexity will require “rationally designed therapeutic combinations” that create biological synergies. He said the company has built a “diversified toolkit” that includes immunomodulators, antibody-drug conjugates (ADCs), and mRNA cancer immunotherapies.

Sahin outlined three priorities for 2026:

• Accelerate late-stage development of oncology assets, with “key late-stage data readouts” anticipated this year.
• Build momentum in combination therapy, expanding a strategy centered on pumitamab as a potential next-generation immuno-oncology backbone, including combination trials with ADCs and a recently announced partnership with Boehringer Ingelheim.
• Shift from a platform-centric to a tumor-centric development approach focused on high-incidence cancers such as lung and breast cancer.

Sahin also referenced a March announcement to pursue “next-generation mRNA innovations” in a new independent company founded and led by Sahin and Chief Medical Officer and Co-founder Özlem Türeci. He said planning “at arm’s length is ongoing” and BioNTech expects to share agreement details later this year.

Looking further out, Sahin said BioNTech is targeting more than 17 late-stage and pivotal trial readouts through 2030 and aims to become a “diversified multi-product oncology company by 2030.”

Pipeline updates: lung cancer data and pivotal trials

Türeci said BioNTech’s clinical development strategy aims to address “the full continuum of cancer,” from early high-risk settings to advanced and refractory disease, with key focus areas including lung cancer and breast cancer.

In lung cancer, Türeci highlighted pumitamab, described as a PD-L1/VEGF-A bispecific antibody and the “IO backbone” of the company’s combination strategy. She said BioNTech presented phase I-B/II-A monotherapy data at the European Lung Cancer Congress in March in previously untreated advanced non-small cell lung cancer patients (squamous and non-squamous). In patients with PD-L1 expression of at least 1%, she cited:

• Confirmed objective response rate (ORR) of 46%
• Median progression-free survival (PFS) of 13.6 months
• Median overall survival (OS) of 27 months
• Disease control rate of 96%

Türeci emphasized activity across PD-L1 subgroups and said the response rate was “particularly strong” in PD-L1 high squamous disease at 71%. She said tolerability was “manageable,” with a low discontinuation rate.

She said the global phase III ROSETTA LUNG-02 trial is recruiting in its phase III portion, comparing pumitamab plus chemotherapy to pembrolizumab plus chemotherapy in first-line non-small cell lung cancer, with phase II data expected to be presented at ASCO 2026.

During Q&A, Sahin addressed the previously disclosed change to ROSETTA LUNG-02’s primary endpoint. He said the company made PFS the single primary endpoint because PFS is “well-accepted” in non-small cell lung cancer and BioNTech expects “the largest and earliest benefit signal” there, allowing the company to “allocate the full alpha” to PFS for a statistically robust readout. He said overall survival remains a “key secondary endpoint.” On a later question about regulatory implications, Sahin said the decision was discussed with partner Bristol Myers Squibb and regulators, and that PFS as the primary endpoint provides the “earliest potential readout” while keeping OS as a key secondary endpoint.

Gotistobart and T-Pam: regulatory designations and late-stage enrollment

Türeci also discussed gotistobart, described as a selective Treg modulator targeting CTLA-4 developed with OncoC4, aimed at metastatic squamous non-small cell lung cancer patients who progressed after platinum chemotherapy and PD-1/PD-L1 therapy. She said gotistobart received FDA orphan drug designation for squamous non-small cell lung cancer in January, adding to an existing fast-track designation.

She highlighted updated data presented at ELCC from the non-pivotal dose confirmation stage of the global phase III PRESERVE-003 trial, including a 12-month PFS rate of 25% for gotistobart versus 0% for docetaxel and a 54% reduction in risk of death versus docetaxel (hazard ratio 0.46). She said median OS in the gotistobart arm had not been reached versus approximately 10 months with docetaxel, and at 12 months 63% of gotistobart-treated patients were alive versus 30% for docetaxel. Türeci cautioned that the data were from a small patient population and “require further validation,” and said interim data from the pivotal stage are expected later this year based on event accrual projections.

In gynecologic cancers, Türeci reviewed updated data for trastuzumab pamirtecan (T-Pam), a HER2-targeted ADC developed with DualityBio, presented at the Society of Gynecologic Oncology annual meeting in April in previously treated advanced or metastatic endometrial cancer. She said T-Pam demonstrated a confirmed ORR of 49%, median duration of response of 9.9 months, and disease control rate of 79%, with responses observed across HER2 IHC 1+, 2+, and 3+ expression levels. She said the safety profile was manageable and consistent with what has been reported for ADCs and HER2-targeted agents in the setting.

Türeci said the confirmatory phase III Fern EC-01 trial continues to enroll. She also said T-Pam is being evaluated in a phase III trial in HR-positive, HER2-low metastatic breast cancer (DYNASTY-Breast02), with an interim analysis expected later this year based on event accrual.

In Q&A, Türeci said the company is “in discussion with the FDA” and that BioNTech has not changed its plans to submit for T-Pam. Later, she said BioNTech does not have outstanding data questions for T-Pam, but is monitoring confirmatory trial enrollment to align BLA submission timing with confirmatory data timelines. She said BioNTech is interested in a “broad label,” citing a large dataset across HER2 IHC levels including low expression.

mRNA immunotherapy programs and upcoming readouts

Türeci provided updates on BioNTech’s mRNA cancer immunotherapy efforts, including personalized autogene cevumeran partnered with Roche Genentech. She said BioNTech’s focus is on the adjuvant setting, where tumor burden and heterogeneity are lower. She highlighted long-term follow-up data from a pancreatic ductal adenocarcinoma phase I trial presented at AACR: among eight patients who mounted an immune response, seven remained alive up to six years after surgery with persistent cytotoxic lymphocytes; among eight patients without an immune response, two were still alive with a median OS of 3.4 years.

She also outlined timelines for other programs, including a phase II autogene cevumeran trial in ctDNA-positive stage 2 high-risk or stage 3 colorectal cancer with final analysis expected in 2027, and a phase II-III FixVac trial (BNT113) in first-line HPV16-positive PD-L1 high head and neck squamous cell carcinoma in combination with pembrolizumab, with recruitment ongoing and a phase III interim analysis expected in 2026. In response to an analyst question on timing, management reiterated guidance for interim readouts in the second half of 2026 for gotistobart and FixVac, adding the company would inform the market when the interim analyses occur.

Financial results, guidance, and capital allocation

Chief Financial Officer Ramon Zapatero said first-quarter 2026 performance was in line with expectations and reflected seasonal COVID-19 vaccine demand. Revenue for the quarter was €118 million, down from €183 million a year earlier, primarily due to lower COVID-19 vaccine demand.

R&D expenses were €557 million versus €526 million in the prior-year period, driven by higher spending on immuno-oncology and ADC programs—“in particular, pumitamab and gotistobart”—as well as R&D costs from BioNTech China (previously named Biotheus) and CureVac, acquired in 2025. Zapatero said these increases were partly offset by lower expenses from the COVID-19 vaccine collaboration with Pfizer. Adjusted R&D expenses were €527 million, excluding an impairment charge for an intangible asset.

SG&A expenses were €151 million compared to €121 million, driven by commercial build-up and post-acquisition operations; adjusted SG&A was the same as IFRS. BioNTech ended the quarter with €16.8 billion in cash, cash equivalents, and security investments.

Zapatero reaffirmed full-year 2026 guidance (adjusted, non-IFRS), including revenue of €2.0 billion to €2.3 billion, adjusted R&D of €2.2 billion to €2.5 billion, and adjusted SG&A of €700 million to €800 million. He reiterated expectations for lower COVID-19 vaccine revenue versus 2025 due to declines in the U.S. and Europe and noted revenue phasing similar to last year, with the last four months driving most of the year’s revenue. He said a €613 million VMS collaboration payment is expected to be recognized in the third quarter of 2026.

On capital allocation, Zapatero announced plans to initiate a share repurchase program of up to $1 billion in ADS over 12 months, describing it as providing “opportunistic flexibility” while keeping the pipeline as the primary value driver. He also detailed a manufacturing footprint consolidation plan, saying BioNTech intends to exit operations at a manufacturing site in Idar-Oberstein, Marburg, or Singapore, as well as contract sites, affecting “just over 1,800 positions.” BioNTech is exploring divestment options through the end of the third quarter of 2026, and Zapatero said once fully implemented the measures are expected to deliver approximately €500 million in recurring annual savings. He added that Pfizer is expected to fully handle COVID-19 vaccine supply via its manufacturing capacities beginning at the end of 2026.

About BioNTech NASDAQ: BNTX

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.